OBJECTIVE: To establish the prevalence of @entity1887 ( @entity1887 ) in @entity1 with @entity5202 treated with swallowed @entity5023 (FP) or @entity4184 . STUDY DESIGN: @entity1 treated with FP or @entity4184 for >= 6  months underwent a low-dose adrenocorticotropin stimulation test. @entity1 using systemic, inhaled, intranasal, or topical glucocorticoids were excluded. The primary outcome is @entity1887 , defined as peak serum @entity701 <18   g/dL ( <=495  nmol/L). RESULTS: Of 58 @entity1 (81% male), 67% were on FP (median age 13.7  years [range 4.3-19.1], dose 1320   g/d [440-1760], treatment duration 4.0  years [0.6-13.5]). Thirty-three percent were on @entity4184 (median age 10.7  years [range 3.2-17.2], dose 1000   g/d [500-2000], treatment duration 3.4  years [0.6-7.7]). The overall prevalence of abnormal peak @entity701 response ( <=20   g/dL) was 15% (95% CI 6%-25%) (indeterminate [18-20   g/dL] 5% [n  =  3] vs @entity1887 [<18   g/dL] 10% [n  =  6]). All @entity1 on @entity4184 had a normal response vs only 77% of @entity1 on FP (P  =  .02), all of whom were taking FP at a dose >440   g/d. CONCLUSIONS: @entity1887 was present in 10% of @entity1 treated with swallowed glucocorticoids for >= 6  months and was found only in those treated with FP >440   g/d. We recommend low-dose adrenocorticotropin stimulation testing in @entity1 treated long term with high dose FP to allow early detection of @entity1887 .

XXXX after Chronic Swallowed Glucocorticoid Therapy for @entity5202 .

@entity1 :: ('9606', 'Species') :: ['children', 'Patients', 'patients', 'Children'] @entity5202 :: ('MESH:D057765', 'Disease') :: ['eosinophilic esophagitis'] @entity1887 :: ('MESH:D000309', 'Disease') :: ['adrenal insufficiency', 'AI'] @entity4184 :: ('MESH:D019819', 'Chemical') :: ['budesonide'] @entity701 :: ('MESH:D006854', 'Chemical') :: ['cortisol'] @entity5023 :: ('MESH:C065382', 'Chemical') :: ['fluticasone propionate']
@entity1887 :: (MESH:D000309,Disease) :: ['Adrenal Insufficiency']
